Biogen Inkomsten in het verleden

Verleden criteriumcontroles 3/6

De winst van Biogen is gedaald met een gemiddeld jaarlijks percentage van -30.4%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 9.8% per jaar. Het rendement op het eigen vermogen Biogen bedraagt 9.9% en de nettomarge bedraagt 16.8%.

Belangrijke informatie

-30.4%

Groei van de winst

-24.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-9.8%
Rendement op eigen vermogen	9.9%
Nettomarge	16.8%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16

Opbrengsten en kosten

Hoe Biogen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:BIIB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	9,608	1,615	2,316	2,067
30 Jun 24	9,672	1,159	2,489	2,212
31 Mar 24	9,663	1,167	2,476	2,333
31 Dec 23	9,836	1,161	2,502	2,458
30 Sep 23	9,993	1,462	2,532	2,490
30 Jun 23	9,972	2,665	2,343	2,303
31 Mar 23	10,105	3,131	2,379	2,248
31 Dec 22	10,173	3,047	2,409	2,229
30 Sep 22	10,363	2,865	2,570	2,325
30 Jun 22	10,634	2,059	2,661	2,478
31 Mar 22	10,820	1,450	2,726	2,535
31 Dec 21	10,982	1,556	2,680	2,497
30 Sep 21	11,101	1,546	2,700	3,522
30 Jun 21	11,698	1,918	2,619	3,960
31 Mar 21	12,604	3,012	2,536	4,023
31 Dec 20	13,445	4,001	2,516	3,985
30 Sep 20	14,263	5,082	2,370	2,949
30 Jun 20	14,487	5,927	2,351	2,348
31 Mar 20	14,422	5,879	2,365	2,178
31 Dec 19	14,378	5,889	2,359	2,273
30 Sep 19	14,233	5,396	2,285	2,193
30 Jun 19	14,072	5,294	2,229	2,160
31 Mar 19	13,812	4,667	2,176	2,664
31 Dec 18	13,453	4,431	2,109	2,597
30 Sep 18	13,234	3,187	2,070	2,573
30 Jun 18	12,872	2,968	2,007	2,512
31 Mar 18	12,594	2,964	1,921	2,327
31 Dec 17	12,274	2,539	1,936	2,254
30 Sep 17	11,839	3,486	1,859	2,200
30 Jun 17	11,717	3,293	1,887	2,283
31 Mar 17	11,533	3,480	1,949	1,959
31 Dec 16	11,449	3,703	1,950	1,973
30 Sep 16	11,416	3,885	2,035	1,981
30 Jun 16	11,238	3,818	2,051	1,972
31 Mar 16	10,936	3,695	2,050	1,990
31 Dec 15	10,764	3,547	2,113	2,013
30 Sep 15	10,565	3,599	2,104	1,971
30 Jun 15	10,299	3,490	2,196	1,869
31 Mar 15	10,128	3,277	2,281	1,825
31 Dec 14	9,703	2,935	2,232	1,893
30 Sep 14	9,028	2,509	2,154	1,816
30 Jun 14	8,345	2,139	1,990	1,808
31 Mar 14	7,647	1,916	1,844	1,689
31 Dec 13	6,932	1,862	1,712	1,444

Kwaliteitswinsten: BIIB heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (16.8%) BIIB } zijn hoger dan vorig jaar (14.6%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van BIIB is de afgelopen 5 jaar met 30.4% per jaar gedaald.

Versnelling van de groei: De winstgroei van BIIB over het afgelopen jaar ( 10.5% ) overtreft het 5-jarig gemiddelde ( -30.4% per jaar).

Winst versus industrie: De winstgroei BIIB over het afgelopen jaar ( 10.5% ) overtrof de Biotechs -sector 16.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 9.9% ) van BIIB wordt als laag beschouwd.

Biogen Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Recent updates

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Stock: Cheapish, But With Few Growth Prospects

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Opbrengsten en kosten